En développement
Santé·18/06/2026Résumé IA
US Health Advisers Debate New mRNA Flu Vaccine
US health advisers are reviewing Moderna's new mRNA flu vaccine, mFlusiva, for individuals 50 and older. The vaccine, similar to those used for COVID-19, showed a 27% reduction in flu cases in a study. The FDA is assessing its safety and efficacy, with a decision expected before the winter flu season.
G
Guardian International2 min de lecture
